Logo

Genentech's Tecentriq Receives the US FDA's Approval as Adjuvant Treatment for Early Non-Small Cell Lung Cancer

Share this
Genentech's Tecentriq Receives the US FDA's Approval as Adjuvant Treatment for Early Non-Small Cell Lung Cancer

Tuba Khan

Genentech's Tecentriq Receives the US FDA's Approval as Adjuvant Treatment for Early Non-Small Cell Lung Cancer

Shots:

  • The approval is based on P-III IMpower010 study Tecentriq vs BSC in 1005 patients in a ratio (1:1) with Stage IB-IIIA NSCLC- following surgical resection and up to 4 cycles of adjuvant cisplatin-based CT
  • The results showed a 34% reduction in risk of disease recurrence or death in people with Stage II-IIIA NSCLC whose tumors express PD-L1≥1%- safety data were consistent with known safety profile & no new safety signals were observed
  • The FDA has reviewed & approved the supplemental application under the RTOR program for safe & effective treatments to patients imminently. The company has an extensive program for Tecentriq including ongoing & planned P-III studies for multiple cancers

Click here to­ read the full press release/ article | Ref: Businesswire | Image: Xconomy

Click Here

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family